Surgical adjuvant chemotherapy in cancer of the breast: results of a decade of cooperative investigation.
作者信息
Fisher B, Ravdin R G, Ausman R K, Slack N H, Moore G E, Noer R J
出版信息
Ann Surg. 1968 Sep;168(3):337-56. doi: 10.1097/00000658-196809000-00004.
Abstract
摘要
相似文献
1
Surgical adjuvant chemotherapy in cancer of the breast: results of a decade of cooperative investigation.乳腺癌的手术辅助化疗：十年合作研究的结果
Ann Surg. 1968 Sep;168(3):337-56. doi: 10.1097/00000658-196809000-00004.
2
Extended surgical adjuvant thiotepa for mammary carcinoma.
Arch Surg. 1974 Aug;109(2):187-92. doi: 10.1001/archsurg.1974.01360020049010.
3
Extended surgical adjuvant chemotherapy for breast carcinoma.
Am J Surg. 1969 May;117(5):701-4. doi: 10.1016/0002-9610(69)90409-7.
4
Controversies in the management of potentially curable breast cancer.
Surg Annu. 1974;6:247-81.
5
Systemic chemotherapy as an adjuvant to surgery in the treatment of breast cancer.全身化疗作为乳腺癌手术的辅助治疗手段。
Cancer. 1969 Dec;24(6):1286-9. doi: 10.1002/1097-0142(196912)24:6<1286::aid-cncr2820240639>3.0.co;2-7.
6
Therapeutic implications from a mathematical model characterizing the course of breast cancer.
Cancer. 1969 Nov;24(5):960-71. doi: 10.1002/1097-0142(196911)24:5<960::aid-cncr2820240515>3.0.co;2-u.
7
Chemotherapy in primary therapy of cancer of the breast.
Cancer. 1967 Jul;20(7):1054-5. doi: 10.1002/1097-0142(196707)20:7<1054::aid-cncr2820200706>3.0.co;2-1.
8
[Late results of observing patients with extensive breast cancer who have undergone chemotherapy by infusion].
Vopr Onkol. 1974;20(1):6-11.
9
The relationship of menstrual status and other risk factors to recurrence of carcinoma of the breast.月经状况及其他危险因素与乳腺癌复发的关系。
Am J Epidemiol. 1972 Sep;96(3):173-82. doi: 10.1093/oxfordjournals.aje.a121446.
10
Evidence of a castration-mediated effect of adjuvant cytotoxic chemotherapy in premenopausal breast cancer.辅助细胞毒性化疗对绝经前乳腺癌的去势介导作用的证据。
J Clin Oncol. 1987 Nov;5(11):1771-8. doi: 10.1200/JCO.1987.5.11.1771.
引用本文的文献
1
The Decline and Fall of the Current Chemotherapy Paradigm in Soft Tissue Sarcoma.软组织肉瘤当前化疗模式的衰落
Cancers (Basel). 2025 Apr 1;17(7):1203. doi: 10.3390/cancers17071203.
2
Navigating Breast Cancer Oligometastasis and Oligoprogression: Current Landscape and Future Directions.乳腺癌寡转移和寡进展的诊治：现状与未来方向。
Curr Oncol Rep. 2024 Jun;26(6):647-664. doi: 10.1007/s11912-024-01529-2. Epub 2024 Apr 23.
3
Axillary nodal staging in breast cancer: what have we learned?乳腺癌腋窝淋巴结分期：我们学到了什么？
Clin Exp Metastasis. 2024 Aug;41(4):375-380. doi: 10.1007/s10585-023-10262-2. Epub 2024 Jan 13.
4
COL11A1 serves as a biomarker for poor prognosis and correlates with immune infiltration in breast cancer.COL11A1作为乳腺癌预后不良的生物标志物，与免疫浸润相关。
Front Genet. 2022 Sep 9;13:935860. doi: 10.3389/fgene.2022.935860. eCollection 2022.
5
Evolution of Medical Approaches and Prominent Therapies in Breast Cancer.乳腺癌医学治疗方法及主要疗法的演变
Cancers (Basel). 2022 May 16;14(10):2450. doi: 10.3390/cancers14102450.
6
The double agents in liquid biopsy: promoter and informant biomarkers of early metastases in breast cancer.液体活检中的双重间谍：乳腺癌早期转移的促进因子和信息生物标志物。
Mol Cancer. 2022 Apr 4;21(1):95. doi: 10.1186/s12943-022-01506-y.
7
Are we closer to being able to select patients with node-positive hormone receptor-positive breast cancer who can safely omit chemotherapy?我们是否更接近于能够挑选出那些可以安全地省略化疗的淋巴结阳性、激素受体阳性乳腺癌患者？
Ther Adv Med Oncol. 2022 Mar 26;14:17588359221084769. doi: 10.1177/17588359221084769. eCollection 2022.
8
Exploring the Evolving Scope of Neoadjuvant Immunotherapy in NSCLC.探索非小细胞肺癌新辅助免疫治疗不断演变的范围
Cancers (Basel). 2022 Jan 31;14(3):741. doi: 10.3390/cancers14030741.
9
Concordance assessment of Watson for Oncology in breast cancer chemotherapy: first China experience.乳腺癌化疗中Watson肿瘤学系统的一致性评估：中国首例经验
Transl Cancer Res. 2019 Apr;8(2):389-401. doi: 10.21037/tcr.2019.01.34.
10
A Short History of Bernard Fisher's Contributions to Randomized Clinical Trials.伯纳德·费舍尔对随机临床试验贡献的简史。
Clin Trials. 2022 Apr;19(2):127-136. doi: 10.1177/17407745211066498. Epub 2022 Jan 6.
本文引用的文献
1
I. The Results of Operations for the Cure of Cancer of the Breast Performed at the Johns Hopkins Hospital from June, 1889, to January, 1894.一、1889年6月至1894年1月在约翰·霍普金斯医院进行的乳腺癌治疗手术结果。
Ann Surg. 1894 Nov;20(5):497-555. doi: 10.1097/00000658-189407000-00075.
2
3
ADJUVANT CHEMOTHERAPY. THIO-TEPA WITH RADICAL MASTECTOMY IN THE TREATMENT OF BREAST CANCER.
Am J Surg. 1963 Sep;106:405-12. doi: 10.1016/0002-9610(63)90123-5.
4
Maximum utilization of the life table method in analyzing survival.在分析生存情况时最大限度地利用生命表法。
J Chronic Dis. 1958 Dec;8(6):699-712. doi: 10.1016/0021-9681(58)90126-7.
5
6
The prophylactic treatment of malignant disease with nitrogen mustard and triethylenethiophosphoramide (thio-TEPA).用氮芥和三乙烯硫代磷酰胺（硫代TEPA）对恶性疾病进行预防性治疗。
Ann Surg. 1957 May;145(5):624-9. doi: 10.1097/00000658-195705000-00002.
7
Prophylactic treatment of cancer; the use of chemotherapeutic agents to prevent tumor metastasis.癌症的预防性治疗；使用化疗药物预防肿瘤转移。
Surgery. 1956 Aug;40(2):291-6.
8
The cytologic demonstration and significance of tumor cells in the mesenteric venous blood in patients with colorectal carcinoma.结直肠癌患者肠系膜静脉血中肿瘤细胞的细胞学显示及其意义
Surg Gynecol Obstet. 1955 Jan;100(1):102-8.
9
Is there an increased risk?风险是否增加？
Fed Proc. 1954 Sep;13(3):815-9.
10
A commentary. Selected considerations regarding chemotherapy as adjuvant in cancer treatment.一篇评论。关于化疗作为癌症治疗辅助手段的若干考量。
Cancer Chemother Rep. 1966 Jan-Feb;50(1):1-8.
Zotero 插件